Zai Lab’s ROS1 Inhibitor Augtyro Earns NMPA Nod for Advanced NSCLC Treatment
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, has announced...
HKG: 9688
Zai Lab’s Q1 2024 Revenue Rises 43% YOY on Strong Product Launch and NRDL Inclusion
Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) has announced its financial results for the first...
Zai Lab Ltd Appoints New Greater China CCO as Liang Yi Exits
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the appointment of Zhu Tong as...
Zai Lab Announces Positive Phase III Data for Krazati in KRASG12C-mutated NSCLC, Plans NDA Filing in China
Zai Lab (NASDAQ: ZLAB; HKG: 9688), a China-based biotech company, has announced positive Phase III...
Zai Lab and Novocure Report Positive Phase III Results for TTFields in NSCLC Brain Metastases
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, and Novocure...
Zai Lab Ltd Reports 31% YOY Growth in Product Revenues and Strategic Pipeline Expansion
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has released its financial...
Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC
Medilink Therapeutics, a Suzhou-based biopharmaceutical company, has entered into a global collaboration and licensing agreement...
BMS to Acquire Karuna Therapeutics for $14 Billion, Expanding Psychosis Treatment Portfolio
Bristol Myers Squibb (BMS; NYSE: BMY), a leading US pharmaceutical company, has announced its intention...
CDE Indicates BTD Status for Visirna’s VSA001, Sperogenix’s Vamorolone, and Zai Lab’s Efgartigimod
The Center for Drug Evaluation (CDE) website has indicated that Visirna Therapeutics’ novel siRNA therapy...
Zai Lab’s Margenza (Margetuximab) Approved by China’s NMPA for HER2-Positive Breast Cancer
The National Medical Products Administration (NMPA) website has indicated that Zai Lab Ltd’s (NASDAQ: ZLAB,...
Novocure’s TTFields Misses Overall Survival Endpoint in Ovarian Cancer Phase III Trial
Switzerland-based Novocure (NASDAQ: NVCR) has experienced a setback with its Tumor Treating Fields (TTFields) product,...
Zai Lab Ltd Reports Q2 2023 Financials with 53% YOY Product Revenue Growth
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its financial results for the...
Zai Lab and argenx Report Positive Preliminary Results from Vyvgart Hytrulo CIDP Study
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its Netherlands-based partner argenx SE (NASDAQ:...
Zai Lab Initiates Phase III Trial for Bemarituzumab in First-Line Gastric Cancer Treatment
China-based biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the first patient...
Zai Lab’s Vyvgart Receives NMPA Review for Subcutaneous Injection Form in gMG Treatment
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced that the National Medical Products...
Zai Lab’s Vyvgart Receives NMPA Approval as First-in-Class FcRn Antagonist for Myasthenia Gravis
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has announced that the...
Zai Lab and Novocure’s TTFields Show Survival Benefit in NSCLC, Despite Stock Plunge
China-based Zai Lab Ltd (ZLAB) (NASDAQ: ZLAB; HKG: 9688) and its partner Novocure Ltd (NASDAQ:...
Zai Lab Limited Reports Q1 2023 Financial Results and Product Highlights
China-based Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) has announced its financial results for the...
Zai Lab Partners with MediLink Therapeutics to Develop YL212 DLL3 ADC
Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688), a China-based biopharmaceutical company, has announced a strategic...
Zai Lab Reports 2022 Financial Results with Revenue Growth
China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has announced its full-year 2022 financial results,...